Defective D-loop formation mediated by PALB2, BRCA2 and RAD51 due to loss-of-function of PALB2 in BRCA1 binding

Stable Identifier
R-HSA-9704330
Type
Reaction [transition]
Species
Homo sapiens
Compartment
nucleoplasm
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
Defective D-loop formation mediated by PALB2, BRCA2 and RAD51 due to loss-of-function of PALB2 in BRCA1 binding
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
The coiled-coil domain at the N-terminus of PALB2 represents a hotspot for mutations in PALB2. Several PALB2 missense mutants have been characterized either in targeted studies (Sy et al. 2009, Foo et al. 2017, Song et al. 2018) or as part of high throughput approaches to characterize clinical variants of uncertain significance (reviewed in Boonen et al. 2020).

The following PALB2 missense mutants have been shown to be at least partially defective in their ability to bind to BRCA1 (some of these mutants were also shown to be defective in their ability to homodimerize and to promote homologous recombination repair (HRR); in addition, some have been shown to confer sensitivity to DNA damaging agents or to PARP inhibitors):
PALB2 L21A (originally studied as a synthetic mutant with an amino acid substitution at one of the coiled-coil domain residues of PALB2 that are critical for BRCA1 binding and homodimerization (Sy et al. 2009, Song et al. 2018); this mutant has also been reported clinically, in Clingen Allele Registry (Pawliczek et al. 2018), as a consequence of an in-frame indel in PALB2)
PALB2 L24S (Boonen et al. 2019; Wiltshire et al. 2020; also shown to be defective in HRR (Boonen et al. 2019, Wiltshire et al. 2020), confer sensitivity to cisplatin (Wiltshire et al. 2020) and PARP inhibitor olaparib (Wiltshire et al. 2020))
PALB2 Y28C (partially impaired in BRCA1 binding, Foo et al. 2017; significantly impaired BRCA1 binding, Rodrigue et al. 2019; does not disrupt PALB2 self-interaction (Foo et al. 2017); not significantly defective in HRR and does not confer sensitivity to DNA damaging agents and PARP inhibitors (Foo et al. 2017); partially defective in HRR (Rodrigue et al. 2019, Wiltshire et al. 2020) and significantly sensitive to cisplatin and PARP inhibition (Boonen et al. 2019))
PALB2 L35P (Foo et al. 2017, Rodrigue et al. 2019, Boonen et al. 2019, Wiltshire et al. 2020; does not disrupt PALB2 self-interaction (Foo et al. 2017); also shown to be defective in HRR (Foo et al. 2017, Rodrigue et al. 2019, Boonen et al. 2019, Wiltshire et al. 2020), confer sensitivity to platinum salts (Foo et al. 2017, Boonen et al. 2019, Wiltshire et al. 2020), and confer sensitivity to PARP inhibitors (Foo et al. 2017, Boonen et al. 2019, Wiltshire et al. 2020))
PALB2 R37H (not significantly affected in BRCA1 binding, Foo et al. 2017; partially impaired in BRCA1 binding, Boonen et al. 2019; partially defective in HRR (Foo et al. 2017, Rodrigue et al. 2019, Boonen et al. 2019, Wiltshire et al. 2020))

Interestingly, some of the PALB2 variants that show a defective interaction with BRCA1, such as PALB2 L24S, PALB2 Y28C, and PALB2 L35P, seem to have slightly elevated protein levels (Foo et al. 2017, Boonen et al. 2019, Wiltshire et al. 2020).

Synthetic PALB2 mutants generated by directed mutagenesis, PALB2 L21P (Zhang et al. 2009), PALB2 L24P (Zhang et al. 2009), PALB2 Y28A (Sy et al. 2009) and PALB2 L35A (Sy et al. 2009) are also unable to bind BRCA1 and show impaired homologous recombination function.

The following PALB2 mutants, reported in cancer and predicted to be pathogenic, have not been functionally studied and are annotated as candidate loss-of-function mutants for BRCA1 binding based on their sequence similarity with functionally studied PALB2 mutants:
PALB2 L21F (similar to PALB2 L21A)
PALB2 L35F (similar to the synthetic mutant PALB2 L35A, described by Sy et al. 2009 and to the functionally characterized cancer-associated mutant PALB2 L35P)
PALB2 R37C (similar to PALB2 R37H)
PALB2 E12* (truncation mutants that lacks the coiled coil domain involved in BRCA1 binding, which maps to residues 9-42, as described by Sy et al. 2009; this truncation mutant may be a null mutant as the protein is predicted to have only the first 11 amino acids).

A comprehensive list of variants in the PALB2 gene is provided at the Leiden Open Variation Database (LOVD) (https://databases.lovd.nl/shared/genes/PALB2) (Fokkema et al. 2011).
Literature References
PubMed ID Title Journal Year
21520333 LOVD v.2.0: the next generation in gene variant databases

Fokkema, IF, Taschner, PE, Schaafsma, GC, Celli, J, Laros, JF, den Dunnen, JT

Hum Mutat 2011
19369211 PALB2 is an integral component of the BRCA complex required for homologous recombination repair

Sy, SM, Huen, MS, Chen, J

Proc Natl Acad Sci U S A 2009
30289697 Antiparallel Coiled-Coil Interactions Mediate the Homodimerization of the DNA Damage-Repair Protein PALB2

Song, F, Li, M, Liu, G, Swapna, GVT, Daigham, NS, Xia, B, Montelione, GT, Bunting, SF

Biochemistry 2018
30311374 ClinGen Allele Registry links information about genetic variants

Pawliczek, P, Patel, RY, Ashmore, LR, Jackson, AR, Bizon, C, Nelson, T, Powell, B, Freimuth, RR, Strande, N, Shah, N, Paithankar, S, Wright, MW, Dwight, S, Zhen, J, Landrum, M, McGarvey, P, Babb, L, Plon, SE, Milosavljevic, A, Clinical Genome (ClinGen) Resource, -

Hum. Mutat. 2018
31757951 Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2

Boonen, RACM, Rodrigue, A, Stoepker, C, Wiegant, WW, Vroling, B, Sharma, M, Rother, MB, Celosse, N, Vreeswijk, MPG, Couch, F, Simard, J, Devilee, P, Masson, JY, van Attikum, H

Nat Commun 2019
28319063 Compromised BRCA1-PALB2 interaction is associated with breast cancer risk

Foo, TK, Tischkowitz, M, Simhadri, S, Boshari, T, Zayed, N, Burke, KA, Berman, SH, Blecua, P, Riaz, N, Huo, Y, Ding, YC, Neuhausen, SL, Weigelt, B, Reis-Filho, JS, Foulkes, WD, Xia, B

Oncogene 2017
31636395 Functional characterization of 84 PALB2 variants of uncertain significance

Wiltshire, T, Ducy, M, Foo, TK, Hu, C, Lee, KY, Belur Nagaraj, A, Rodrigue, A, Gomes, TT, Simard, J, Monteiro, ANA, Xia, B, Carvalho, MA, Masson, JY, Couch, FJ

Genet Med 2020
33195396 Functional Characterization of PALB2 Variants of Uncertain Significance: Toward Cancer Risk and Therapy Response Prediction

Boonen, RACM, Vreeswijk, MPG, van Attikum, H

Front Mol Biosci 2020
31586400 A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor

Rodrigue, A, Margaillan, G, Torres Gomes, T, Coulombe, Y, Montalban, G, da Costa E Silva Carvalho, S, Milano, L, Ducy, M, De-Gregoriis, G, Dellaire, G, Araújo da Silva, W, Monteiro, AN, Carvalho, MA, Simard, J, Masson, JY

Nucleic Acids Res 2019
  Global Variome shared LOVD PALB2 (partner and localizer of BRCA2)

Tischkowitz, M

   
19584259 PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2

Zhang, F, Fan, Q, Ren, K, Andreassen, PR

Mol Cancer Res 2009
Participants
Input
Participates
as an event of
Normal reaction
D-loop formation mediated by PALB2, BRCA2 and RAD51 (Homo sapiens)
Functional status

Loss of function of PALB2 mutants (BRCA1 binding) [nucleoplasm]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cross References
Mondo
Authored
Orlic-Milacic, M  (2020-10-09)
Reviewed
Winqvist, R  (2021-02-25)
Pospiech, H  (2021-02-25)
Milano de Souza, L  (2021-07-25)
Masson, JY  (2021-07-25)
Created
Orlic-Milacic, M  (2020-10-07)
Cite Us!